

Antibiogram of Selected Pathogens, South Dakota 2017

Gram positive organisms								
Antibiotic	% Susceptible and (n) number of isolates tested							
Amoxicillin/Clavulanic acid								
Cefepime								
Cefotaxime							91(104)	
Ceftriaxone				100(45)	98(71)	99(164)		
Ampicillin					99(150)		97(2071)	18(224)
Oxacillin‡	64(2466)	100(1643)	0(641)					
Penicillin‡	21(3543)	23(1288)	0(447)	100(102)	99(263)	70(626)	97(3351)	16(453)
Ciprofloxacin								
Levofloxacin				100(84)	98(368)	97(1591)		
Clindamycin	74(2478)	82(3520)	67(2095)	↑91(83)	46(255)	87(695)		
Daptomycin	100(76)	99(155)	98(196)				98(210)	
Erythromycin	49(2474)	71(3378)	15(2023)	88(83)		46(838)		
Gentamicin					100(103)		74(3619)	94(467)
Linezolid	100(2435)	100(1523)	100(988)		100(117)	100(233)	98(3777)	97(521)
Nitrofurantoin*	99(1930)	100(3214)	100(1592)				98(3453)	25(483)
Rifampin	99(2216)	99(597)	99(426)					
Trimethoprim/Sulfamethoxazole	98(2470)	96(3548)	98(2120)			76(753)		
Tetracycline	94(2471)	93(3475)	93(2054)	78(46)	10(110)	80(324)	24(2977)	↓19(481)
Vancomycin	100(2435)	100(3548)	100(2068)	100(104)	100(383)	100(759)	99(3853)	↓39(520)
>5% increase in susceptibility from 2013				>5% decrease in susceptibility from 2013				

*Denotes a 10% or greater decrease change in susceptibility compared to data from 2013

†Denotes a 10% or greater Increase change in susceptibility compared to data from 2013

*Urine isolates only

†From laboratories which did not separate MRSA and MSSA. Data included in this column is not included in the MSSA or MRSA columns.

‡Only reported oxacillin and penicillin for Staph. aureus based on CLSI guidelines

CLSI recommends reporting data only if 30 or more isolates analyzed, less than 30 isolates are reported for completeness, but results may not be statistically valid